1. Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting. (17th June 2019) Authors: Ito, Tomoki; Hashimoto, Yoshinori; Tanaka, Yasuhiro; Nakaya, Aya; Fujita, Shinya; Satake, Atsushi; Nakanishi, Takahisa; Konishi, Akiko; Hotta, Masaaki; Yoshimura, Hideaki; Ishii, Kazuyoshi; Hashimoto, Akiko; Kondo, Toshinori; Omura, Hiromi; Shinzato, Isaku; Tanaka, Takayuki; Nomura, Shosaku Journal: European journal of haematology Issue: Volume 103:Number 2(2019) Page Start: 116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Methotrexate-associated primary hepatic malignant lymphoma following hepatectomy: A case report. (2017) Authors: Takei, Daisuke; Abe, Tomoyuki; Amano, Hironobu; Hirano, Naomichi; Kobayashi, Tsuyoshi; Ohdan, Hideki; Kondo, Toshinori; Nakahara, Masahiro; Noriyuki, Toshio Journal: International journal of surgery case reports Issue: Volume 31(2017) Page Start: 5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1. (2021) Authors: Takeuchi, Asako; Kondo, Toshinori; Tasaka, Taizo; Yamada, Seiko; Hirose, Tadashi; Fukuda, Hirofumi; Shimizu, Risa; Matsuhashi, Yoshiko; Kondo, Eisei; Wada, Hideho Journal: Leukemia research reports Issue: Volume 15(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression. Issue 9 (28th July 2016) Authors: Okamoto, Shuichiro; Tsujioka, Takayuki; Suemori, Shin‐ichiro; Kida, Jun‐ichiro; Kondo, Toshinori; Tohyama, Yumi; Tohyama, Kaoru Journal: Cancer science Issue: Volume 107:Issue 9(2016) Page Start: 1302 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗